DAX25.288 +0,1%Est505.981 -0,3%MSCI World4.343 -0,1%Top 10 Crypto12,17 -0,1%Nas23.671 +0,8%Bitcoin77.591 -0,7%Euro1,1684 +0,4%Öl63,10 +0,1%Gold4.593 +1,9%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Novo Nordisk A3EU6F Deutsche Telekom 555750 Bayer BAY001 Allianz 840400 DroneShield A2DMAA Amazon 906866 BASF BASF11 Infineon 623100 RENK RENK73 Siemens Energy ENER6Y Volkswagen (VW) vz. 766403 TKMS thyssenkrupp Marine Systems TKMS00 Lufthansa 823212
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX wenig verändert -- Asiens Börsen letztlich grün -- US-Ölkonzerne vor Investments in Venezuela -- Novo Nordisk, Goldrekord, Rüstungsaktien, Amazon, DroneShieled im Fokus
Top News
Ein-Faktor-ETFs und Multifaktor-ETFs: Das sollten Anleger wissen Ein-Faktor-ETFs und Multifaktor-ETFs: Das sollten Anleger wissen
BE Semiconductor Industries erhält Auftragsplus durch Rechenzentren BE Semiconductor Industries erhält Auftragsplus durch Rechenzentren
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Personalis Aktie

Kaufen
Verkaufen
Personalis Aktien-Sparplan
6,97 EUR +0,07 EUR +1,01 %
STU
8,35 USD -0,03 USD -0,30 %
nachbörslich
BTT
Personalis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.615,48 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PLTK

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS71535D1063

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolPSNL

Personalis Aktien News

DatumMeistgelesen
ZacksPersonalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates
ZacksPersonalis (PSNL) Moves 20.5% Higher: Will This Strength Last?
ZacksDown 27.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Personalis (PSNL)
Wer­bungPersonalis-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
ZacksAfter Plunging 30.5% in 4 Weeks, Here's Why the Trend Might Reverse for Personalis (PSNL)
ZacksAll You Need to Know About Personalis (PSNL) Rating Upgrade to Buy
BenzingaSuper Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
MotleyFoolPersonalis (PSNL) Q2 Revenue Falls 24%
ZacksPersonalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?
ZacksPersonalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock?
ZacksPersonalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
BenzingaWhat 5 Analyst Ratings Have To Say About Personalis
BenzingaA Glimpse Into The Expert Outlook On Personalis Through 7 Analysts
ZacksPersonalis (PSNL) Reports Q4 Loss, Tops Revenue Estimates
ZacksPersonalis (PSNL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
BenzingaPersonalis Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
ZacksPersonalis (PSNL) Upgraded to Buy: Here's Why
BusinesswirePersonalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna
BusinesswirePersonalis and Tempus Expand Collaboration to Biopharma
BusinesswireESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test
BusinesswirePersonalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BusinesswireASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
BusinesswirePersonalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
BusinesswirePersonalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
BusinesswirePersonalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BusinesswireData Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
BusinesswirePersonalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
BusinesswirePersonalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BusinesswirePersonalis Reports Fourth Quarter and Full Year 2023 Financial Results
BusinesswirePersonalis to Announce Fourth Quarter and Full Year 2023 Financial Results
BusinesswirePersonalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology
BusinesswirePersonalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BusinesswirePersonalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay
BusinesswirePersonalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance
BusinesswirePersonalis Extends Cash Position Into 2026, Provides Update on Key Initiatives
BusinesswirePersonalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing
BusinesswirePersonalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer
BusinesswireAnalysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology
BusinesswirePersonalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023
BusinesswirePersonalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

Personalis News

Personalis News: auf dieser Seite finden Sie alle Personalis News und Nachrichten zur Personalis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Personalis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Personalis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.